1
|
Gracheva IA, Svirshchevskaya EV, Shchegravina ES, Malysheva YB, Sitdikova AR, Fedorov AY. Design, Synthesis and In Vitro Biological Activity of Novel C-7 Methylene Congeners of Furanoallocolchicinoids. Pharmaceutics 2023; 15:pharmaceutics15041034. [PMID: 37111520 PMCID: PMC10143105 DOI: 10.3390/pharmaceutics15041034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 03/18/2023] [Accepted: 03/21/2023] [Indexed: 04/29/2023] Open
Abstract
A series of novel heterocyclic colchicine derivatives bearing a C-7 methylene fragment were synthesized via Wittig, Horner-Wadsworth-Emmons and Nenajdenko-Shastin olefination approaches. The in vitro biological activities of the most promising compounds were investigated using MTT assays and cell cycle analyses. Compounds with an electron withdrawing group on the methylene fragment exhibited substantial antiproliferative activity towards COLO-357, BxPC-3, HaCaT, PANC-1 and A549 cell lines. The spatial orientation of the substituent at the double bond significantly influenced its biological activity.
Collapse
Affiliation(s)
- Iuliia A Gracheva
- Department of Organic Chemistry, Nizhny Novgorod State University, Gagarina Av. 23, Nizhny Novgorod 603950, Russia
| | - Elena V Svirshchevskaya
- Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Miklukho-Maklaya 16/10, Moscow 117997, Russia
| | - Ekaterina S Shchegravina
- Department of Organic Chemistry, Nizhny Novgorod State University, Gagarina Av. 23, Nizhny Novgorod 603950, Russia
| | - Yulia B Malysheva
- Department of Organic Chemistry, Nizhny Novgorod State University, Gagarina Av. 23, Nizhny Novgorod 603950, Russia
| | - Alsu R Sitdikova
- Department of Organic Chemistry, Nizhny Novgorod State University, Gagarina Av. 23, Nizhny Novgorod 603950, Russia
| | - Alexey Yu Fedorov
- Department of Organic Chemistry, Nizhny Novgorod State University, Gagarina Av. 23, Nizhny Novgorod 603950, Russia
| |
Collapse
|
2
|
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance. Drug Resist Updat 2023; 68:100951. [PMID: 36841134 DOI: 10.1016/j.drup.2023.100951] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 02/12/2023] [Accepted: 02/12/2023] [Indexed: 02/15/2023]
Abstract
AIMS Microtubule inhibitors are widely used in first line cancer therapy, though drug resistance often develops and causes treatment failure. Colchicine binds to tubulins and inhibits tumor growth, but is not approved for cancer therapy due to systemic toxicity. In this study, we aim to improve the therapeutic index of colchicine through structural modification. METHODS The methoxyl group of the tropolonic ring in colchicine was replaced with amino groups. The cross-resistance of the derivatives with paclitaxel and vincristine was tested. Antitumor effects of target compounds were tested in vivo in A549 and paclitaxel-resistant A549/T xenografts. The interaction of target compounds with tubulins was measured using biological and chemical methods. RESULTS Methylamino replacement of the tropolonic methoxyl group of colchicine increases, while demethylation loses, selective tubulin binding affinity, G2/M arrest and antiproliferation activity. Methylaminocolchicine is more potent than paclitaxel and vincristine to inhibit tumor growth in vitro and in vivo without showing cross-resistance to paclitaxel. Methylaminocolchicine binds to tubulins in unique patterns and inhibits P-gp with a stable pharmacokinetic profile. CONCLUSION Methylanimo replacement of the tropolonic methoxyl group of colchicine increases antitumor activity with improved therapeutic index. Methylaminocolchicine represents a new type of mitotic inhibitor with the ability of overcoming paclitaxel and vincristine resistance.
Collapse
|
3
|
Computational Approaches to the Rational Design of Tubulin-Targeting Agents. Biomolecules 2023; 13:biom13020285. [PMID: 36830654 PMCID: PMC9952983 DOI: 10.3390/biom13020285] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 01/27/2023] [Accepted: 01/31/2023] [Indexed: 02/05/2023] Open
Abstract
Microtubules are highly dynamic polymers of α,β-tubulin dimers which play an essential role in numerous cellular processes such as cell proliferation and intracellular transport, making them an attractive target for cancer and neurodegeneration research. To date, a large number of known tubulin binders were derived from natural products, while only one was developed by rational structure-based drug design. Several of these tubulin binders show promising in vitro profiles while presenting unacceptable off-target effects when tested in patients. Therefore, there is a continuing demand for the discovery of safer and more efficient tubulin-targeting agents. Since tubulin structural data is readily available, the employment of computer-aided design techniques can be a key element to focus on the relevant chemical space and guide the design process. Due to the high diversity and quantity of structural data available, we compiled here a guide to the accessible tubulin-ligand structures. Furthermore, we review different ligand and structure-based methods recently used for the successful selection and design of new tubulin-targeting agents.
Collapse
|
4
|
Target Identification of 22-(4-Pyridinecarbonyl) Jorunnamycin A, a Tetrahydroisoquinoline Derivative from the Sponge Xestospongia sp., in Mediating Non-Small-Cell Lung Cancer Cell Apoptosis. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27248948. [PMID: 36558080 PMCID: PMC9782168 DOI: 10.3390/molecules27248948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Revised: 12/13/2022] [Accepted: 12/14/2022] [Indexed: 12/23/2022]
Abstract
A dysregulation of the cell-death mechanism contributes to poor prognosis in lung cancer. New potent chemotherapeutic agents targeting apoptosis-deregulating molecules have been discovered. In this study, 22-(4-pyridinecarbonyl) jorunnamycin A (22-(4'py)-JA), a synthetic derivative of bistetrahydroisoquinolinequinone from the Thai blue sponge, was semisynthesized by the Steglich esterification method, and its pharmacological mechanism in non-small-cell lung cancer (NSCLC) was elucidated by a network pharmacology approach. All predicted targets of 22-(4'py)-JA and genes related to NSCLC were retrieved from drug-target and gene databases. A total of 78 core targets were identified, and their associations were analyzed by STRING and Cytoscape. Gene ontology and KEGG pathway enrichment analyses revealed that molecules in mitogen-activated protein kinase (MAPK) signaling were potential targets of 22-(4'py)-JA in the induction of NSCLC apoptosis. In silico molecular docking analysis displayed a possible interaction of ERK1/2 and MEK1 with 22-(4'py)-JA. In vitro anticancer activity showed that 22-(4'py)-JA has strong cytotoxic and apoptosis-inducing effects in H460, H292 and A549 NSCLC cells. Furthermore, immunoblotting confirmed that 22-(4'py)-JA induced apoptotic cell death in an ERK/MEK/Bcl-2-dependent manner. The present study demonstrated that 22-(4'py)-JA exhibited a potent anticancer effect that could be further developed for clinical application and showed that network pharmacology approaches are a powerful tool to illustrate the molecular pathways of new drugs or compounds.
Collapse
|
5
|
Abodo Onambele L, Hoffmann N, Kater L, Hemmersbach L, Neudörfl JM, Sitnikov N, Kater B, Frias C, Schmalz HG, Prokop A. An organometallic analogue of combretastatin A-4 and its apoptosis-inducing effects on lymphoma, leukemia and other tumor cells in vitro. RSC Med Chem 2022; 13:1044-1051. [PMID: 36320328 PMCID: PMC9491352 DOI: 10.1039/d2md00144f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 06/28/2022] [Indexed: 09/19/2023] Open
Abstract
Hexacarbonyl[1,3-dimethoxy-5-((4'-methoxyphenyl)ethynyl)benzene]dicobalt (NAHO27), an organometallic analogue of combretastatin A-4, has been synthesized and its activity against lymphoma, leukemia, breast cancer and melanoma cells has been investigated. It was shown that NAHO27 specifically induces apoptosis in BJAB lymphoma and Nalm-6 leukemia cells at low micromolar concentration and does not affect normal leukocytes in vitro. It also proved to be active against vincristine and daunorubicin resistant leukemia cell lines with p-glycoprotein-caused multidrug resistance and showed a pronounced (550%) synergistic effect when co-applied with vincristine at very low concentrations. Mechanistic investigations revealed NAHO27 to induce apoptosis via the mitochondrial (intrinsic) pathway as reflected by the processing of caspases 3 and 9, the involvement of Bcl-2 and smac/DIABLO, and the reduction of mitochondrial membrane potential. Gene expression analysis and protein expression analysis via western blot showed an upregulation of the proapoptotic protein harakiri by 9%.
Collapse
Affiliation(s)
- Liliane Abodo Onambele
- Department of Pediatric Oncology/Hematology, Children's Hospital of the City of Cologne Amsterdamer Str. 59 50735 Cologne Germany
- Department of Pediatric Oncology/Hematology, University Medical Center Charité Campus Virchow, Augustenburger Pl. 1 13353 Berlin Germany
| | - Natalie Hoffmann
- Department of Chemistry, University of Cologne Greinstrasse 4 50939 Cologne Germany
| | - Lisa Kater
- Department of Pediatric Oncology/Hematology, University Medical Center Charité Campus Virchow, Augustenburger Pl. 1 13353 Berlin Germany
| | - Lars Hemmersbach
- Department of Chemistry, University of Cologne Greinstrasse 4 50939 Cologne Germany
| | - Jörg-Martin Neudörfl
- Department of Chemistry, University of Cologne Greinstrasse 4 50939 Cologne Germany
| | - Nikolay Sitnikov
- Department of Chemistry, University of Cologne Greinstrasse 4 50939 Cologne Germany
| | - Benjamin Kater
- Department of Pediatric Oncology/Hematology, University Medical Center Charité Campus Virchow, Augustenburger Pl. 1 13353 Berlin Germany
| | - Corazon Frias
- Department of Pediatric Oncology/Hematology, University Medical Center Charité Campus Virchow, Augustenburger Pl. 1 13353 Berlin Germany
- Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin 19055 Schwerin Germany
- MSH Medical School Hamburg Am Kaiserkai 1 20457 Hamburg Germany
| | - Hans-Günther Schmalz
- Department of Chemistry, University of Cologne Greinstrasse 4 50939 Cologne Germany
| | - Aram Prokop
- Department of Pediatric Oncology/Hematology, Children's Hospital of the City of Cologne Amsterdamer Str. 59 50735 Cologne Germany
- Department of Pediatric Oncology/Hematology, University Medical Center Charité Campus Virchow, Augustenburger Pl. 1 13353 Berlin Germany
- Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin 19055 Schwerin Germany
- MSH Medical School Hamburg Am Kaiserkai 1 20457 Hamburg Germany
| |
Collapse
|
6
|
Baas J, Bieringer S, Frias C, Frias J, Soehnchen C, Urmann C, Ritter S, Riepl H, Prokop A. Dihydroxyquingdainone Induces Apoptosis in Leukaemia and Lymphoma Cells via the Mitochondrial Pathway in a Bcl-2- and Caspase-3-Dependent Manner and Overcomes Resistance to Cytostatic Drugs In Vitro. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27155038. [PMID: 35956988 PMCID: PMC9370279 DOI: 10.3390/molecules27155038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 07/24/2022] [Accepted: 07/26/2022] [Indexed: 11/16/2022]
Abstract
Isatis tinctoria and its indigo dyes have already provided highly active anti-leukaemic lead compounds, with the focus mainly being on indirubin, whereas indigo itself is inactive. There are many more indigoids to find in this plant extract, for example, quingdainone, an indigoid derived from tryptanthrin. We present here a new synthesis of hitherto neglected substituted quingdainones, which is very necessary due to their poor solubility behaviour, and a structure-dependent anti-leukaemic activity study of a number of compounds. Substituted α-phenylaminoacrylic acid was synthesised by hydrogen sulfide extrusion from an analogue mercaptoacetic acid, available from the condensation of rhodanin and a substituted tryptanthrin. It is shown that just improving water solubility does not increase anti-leukaemic activity, since a quingdainone carboxylic acid is inactive compared to dihydroxyquingdainone. The most effective compound, dihydroxyquingdainone with an AC50 of 7.5 µmole, is further characterised, revealing its ability to overcome multidrug resistance in leukaemia cells (Nalm-6/BeKa) with p-glycoprotein expression.
Collapse
Affiliation(s)
- Jennifer Baas
- Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin, Wismarsche Straße 393-397, 19055 Schwerin, Germany
- Department of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children’s Hospital of the City Cologne, Amsterdamer Straße 59, 50735 Cologne, Germany
| | - Sebastian Bieringer
- Organic-Analytical Chemistry, Weihenstephan-Triesdorf University of Applied Sciences, 94315 Straubing, Germany
- TUM Campus Straubing for Biotechnology and Sustainability, Technical University of Munich, 94315 Straubing, Germany
| | - Corazon Frias
- Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin, Wismarsche Straße 393-397, 19055 Schwerin, Germany
- Department of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children’s Hospital of the City Cologne, Amsterdamer Straße 59, 50735 Cologne, Germany
| | - Jerico Frias
- Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin, Wismarsche Straße 393-397, 19055 Schwerin, Germany
- Department of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children’s Hospital of the City Cologne, Amsterdamer Straße 59, 50735 Cologne, Germany
| | - Carolina Soehnchen
- Medical School Hamburg (MSH), University of Applied Sciences and Medical University, Am Kaiserkai 1, 20457 Hamburg, Germany
| | - Corinna Urmann
- Organic-Analytical Chemistry, Weihenstephan-Triesdorf University of Applied Sciences, 94315 Straubing, Germany
- TUM Campus Straubing for Biotechnology and Sustainability, Technical University of Munich, 94315 Straubing, Germany
| | - Steffi Ritter
- Organic-Analytical Chemistry, Weihenstephan-Triesdorf University of Applied Sciences, 94315 Straubing, Germany
- TUM Campus Straubing for Biotechnology and Sustainability, Technical University of Munich, 94315 Straubing, Germany
| | - Herbert Riepl
- Organic-Analytical Chemistry, Weihenstephan-Triesdorf University of Applied Sciences, 94315 Straubing, Germany
- TUM Campus Straubing for Biotechnology and Sustainability, Technical University of Munich, 94315 Straubing, Germany
- Correspondence: (H.R.); (A.P.)
| | - Aram Prokop
- Department of Pediatric Hematology/Oncology, Helios Clinic Schwerin, Wismarsche Straße 393-397, 19055 Schwerin, Germany
- Department of Pediatric Hematology/Oncology, Municipal Clinics of Cologne, Children’s Hospital of the City Cologne, Amsterdamer Straße 59, 50735 Cologne, Germany
- Medical School Hamburg (MSH), University of Applied Sciences and Medical University, Am Kaiserkai 1, 20457 Hamburg, Germany
- Correspondence: (H.R.); (A.P.)
| |
Collapse
|